Catalent completes acquisition of gene therapy leader

23 May 2019

Acquisition of Paragon Bioservices brings specialized expertise in adeno-associated virus and will enhance Catalent’s biologics business and end-to-end integrated biopharmaceutical solutions for customers.

Catalent has completed the $1.2 billion acquisition of Paragon Bioservices, a leading viral vector development and manufacturing partner for gene therapies.

Catalent completes acquisition of gene therapy leader

With the addition of Paragon’s specialized expertise in adeno-associated virus (AAV) vectors, the most commonly used vector to deliver DNA to cells, Catalent is positioned to capitalize on strong industry tailwinds in the potentially $40 billion addressable market for gene therapies. Paragon also brings to Catalent its unique and differentiated scientific, development, and manufacturing capabilities, which will fundamentally enhance Catalent’s biologics business and end-to-end integrated biopharmaceutical solutions for customers.

Paragon recently announced the opening of its new, state-of-the-art commercial manufacturing center near the Baltimore-Washington International (BWI) airport, which is equipped with several 500-liter and 2,000-liter single-use bioreactors for clinical through commercial material production. The new large-scale production campus – now combined with a recently leased second building which will be built out for commercial GMP manufacturing – has the potential for more than 425,000 square feet of manufacturing space upon completion.

Paragon has GMP manufacturing projects underway with more than half of the top 40 leading gene therapy developers worldwide. Catalent is committed to continuing the resource dedication for Paragon’s customers and maintaining a flexible and reliable development and manufacturing partnership for its clients. The company currently employs over 380 individuals at its two Baltimore-area sites, all of whom will join the existing Catalent team of over 11,000 employees.

Read More

Related news

HALIX starts operational production with new cGMP facility in Q4-2019

HALIX starts operational production with new cGMP facility in Q4-2019

15 Aug 2019

The five-level production facility contains a state-of-the-art manufacturing line for viral vaccines and viral vectors and a separate protein manufacturing area with a capacity up to 1,000-L single-use bioreactors.

Read more 
Delivering complete aseptic vial handling solutions

Delivering complete aseptic vial handling solutions

14 Aug 2019

Bringing freeze drying and vial washing/sterilizing technologies together with advanced and comprehensive vial and syringe filling capabilities.

Read more 
Hikma expands nasal spray capabilities

Hikma expands nasal spray capabilities

12 Aug 2019

Company acquires unit-dose nasal and sublingual spray manufacturing equipment, as well as two pipeline products.

Read more 
How real-world data can revolutionise drug development

How real-world data can revolutionise drug development

9 Aug 2019

Utilising the current data environment and its data pools for the benefit of advancing research.

Read more 
Sartorius launches new services for mammalian cell bank manufacturing

Sartorius launches new services for mammalian cell bank manufacturing

8 Aug 2019

Integrated package of new and established services saves time and minimizes risks.

Read more 
Using mobile phones to fight Alzheimer’s disease

Using mobile phones to fight Alzheimer’s disease

8 Aug 2019

Researchers study how radiofrequency electromagnetic fields could be used in Alzheimer’s disease therapy.

Read more 
Cambrex to be acquired by the Permira funds

Cambrex to be acquired by the Permira funds

7 Aug 2019

The CDMO's shareholders will receive $60.00 per share in cash.

Read more 
Automation-compatible prepared culture media plate technology

Automation-compatible prepared culture media plate technology

6 Aug 2019

Thermo Fisher Scientific's SmartPlate format brings together Oxoid and Remel prepared culture media with a durable, universal plate design, helping customers to deliver accurate results across both automated and manual methods.

Read more 
Colorcon to incorporate TruTag's edible 'optical barcodes' in tablet film coatings

Colorcon to incorporate TruTag's edible 'optical barcodes' in tablet film coatings

6 Aug 2019

The benefits of this innovation include the ability to instantly and unequivocally authenticate products when suspect events.

Read more 
Growing domestic manufacturing creates new opportunities for international pharma in the Middle East

Growing domestic manufacturing creates new opportunities for international pharma in the Middle East

5 Aug 2019

Opportunities abound at CPhI MEA and experts anticipate regional generic companies acting as CMOs for international companies looking to enter the region.

Read more